Compare SDSTW & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDSTW | CLGN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | 10 | 39 |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.0M |
| IPO Year | N/A | 2015 |
| Metric | SDSTW | CLGN |
|---|---|---|
| Price | $0.12 | $0.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 1.3K | ★ 78.9K |
| Earning Date | 03-26-2025 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.27 |
| 52 Week High | $0.30 | $3.23 |
| Indicator | SDSTW | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 50.56 |
| Support Level | $0.11 | $0.36 |
| Resistance Level | $0.12 | $0.45 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.55 | 50.67 |
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.